ClinicalTrials.gg
Not yet recruitingNCT06258525Updated Nov 6, 2026

SAMe in Prevention of Oxaliplatin-associated Liver Injury

A Phase 2 interventional study of Standard of care oxaliplatin-based chemotherapy and S-adenosylmethionine (SAMe) supplement in Colorectal Cancer, Liver Metastases and Liver Metastasis Colon Cancer, sponsored by Cedars-Sinai Medical Center. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Cedars-Sinai Medical Center · Phase 2, Interventional, and Supportive care

Updated Nov 6, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,338 studies in Colorectal Neoplasms with a site in United States — 419 open to participants now, 628 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
1,340th of 1,931
30 · median 64
Started
2027
with 6 others
Phase 2
509 of 2,338
64 open now
Primary completion
2030-01
later than 573 of 626 live
Registered
1,981st of 2,338
by date

Among the 2,338 studies in Colorectal Neoplasms with a site in United States, this one is the 1,340th largest by planned enrollment of the 1,931 interventional ones that give a count, is one of 7 that started in 2027, is one of 509 in phase 2, reaches primary completion later than 573 of the 626 other live ones, and was the 1,981st registered.

Colorectal Neoplasms

6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

419 of the 2,338 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

414 more — sign in →

All 419 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,338 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable colorectal liver metastases. Resectable means that it is able to removed with surgery. Patients will take two SAMe tablets in the morning and one tablet in the evening for 3-6 months (about 6-8 cycles of chemotherapy) in addition to oxaliplatin based chemotherapy followed by surgical removal of the colorectal liver metastases.

03

Conditions studied

  • Colorectal Cancer
  • Liver Metastases
  • Liver Metastasis Colon Cancer
  • Liver Injury
  • Sinusoidal Obstruction Syndrome
  • 5-Fluorouracil Toxicity
  • Liver Toxicity, Chemically-Induced

Keywords

  • S-adenosylmethionine
  • Oxaliplatin
  • Stage IV colorectal cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage IV patients with resectable liver predominant colorectal cancer (new diagnosis or recurrent) referred to Cedars Sinai Medical Center for oxaliplatin based systemic therapy.
  • Age ≥ 18 years.
  • Patients who are planning to undergo liver resection following oxaliplatin based chemotherapy treatment.
  • Performance Status 0-2 or Performance Status (KPS) ≥ 60%.
  • Demonstrate adequate organ and marrow function (within 28 days of study treatment initiation)
  • Female subjects of should have a negative urine or serum pregnancy within 14 days prior to receiving the first dose of study medication for eligibility verification purposes. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Female subjects of childbearing potential should be willing to use adequate methods of (hormonal or barrier method of birth control) or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year.
  • Male subjects should agree to use an adequate method of contraception starting with the first dose of therapy through 120 days after the last dose of therapy.
  • Subjects taking vitamin E ≥800 IU/day must be on a stable dose defined as:

    1. No changes in prescribed dose within 180 days of the screening visit and
    2. No new vitamin E-containing medications within 180 days of the screening visit or
    3. Discontinuation of vitamin E ≥800 IU/day for at least 180 days prior to the screening visit.
  • Subjects taking anti-diabetic medications must be on a stable dose for at least 90 days prior to the date of the screening visit.
  • Written obtained from subject and ability for subject to comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

  • Currently participating in or has participated in a study of an agent or using an investigational device within 4 weeks of the first dose of treatment.
  • No other anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) or investigational agent may be used from 28 days prior to registration and until the end-of-study visit.
  • Has previously received chemotherapy for disease ( or adjuvant therapy is allowed as long as treatment was completed ≥6 months prior to recurrence).
  • Has pre-existing grade ≥ 3 neuropathy precluding use of oxaliplatin.
  • Has known additional that is progressing or requires active treatment.
  • Has a known to any of the study supplement/drugs (SAMe, oxaliplatin, flourouacil, folinic acid and capecitabine).
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
  • Has any gastrointestinal disorder (e.g., bowel obstruction) or neurologic condition (e.g., oropharyngeal dysphagia) that may result in impairment of oral intake, inability to swallow the oral supplement, and/or impairment of absorption of study drug in the opinion of the treating investigator.
  • Has previous clinical diagnosis of cirrhosis, has had known history of Hep A/B/C or nonalcoholic fatty liver disease (NAFLD), liver transplantation, or any other cause for decompensated liver disease.
  • Known (HIV) infection.
  • Any of the following within 6 months prior to the screening visit: unstable cardiovascular disease, myocardial infarction, coronary artery bypass surgery, coronary angioplasty, , or cerebrovascular accident.
  • Any other condition that, in the investigator's opinion, would impede competence or compliance or delay completion of the study.
  • History of Parkinson's disease or bipolar disorder.

Patients taking the following prohibited medications:

  • Olanzapine
  • MAO inhibiters, including:

    • Isocarboxazid
    • Linezolid
    • Methylene blue injection
    • Phenelzine
    • Rasagiline
    • Selegiline
    • Tranylcypromine
    • Any other MAO inhibitors The above prohibited medications cannot be taken -14 days prior to Day 0 and during study treatment.. Patients currently on or plan to be prescribed anti-psychotic medications not listed above may be excluded at the discretion of the Investigator. - Active infection as evidenced by positive urine culture, blood culture, or pneumonia.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Radiation: Standard of care oxaliplatin-based chemotherapy · Dietary Supplement: S-adenosylmethionine (SAMe) supplement · Procedure: Surgery

Interventions

  • RadiationStandard of care oxaliplatin-based chemotherapy

    mFOLFOX6 or CAPOX

  • (400 mg tablet): 2 tablets taken orally AM and 1 tablet PM daily (total 1,200 mg daily) prior to surgical resection

  • ProcedureSurgery

    At 1-Month

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver only stage IV colorectal cancer.

    To identify the effect of SAMe in preventing oxaliplatin associated liver injury as determined by lack of injury on histopathologic analysis in patients with liver only stage IV colorectal cancer. Improvement in liver injury will be measured by the degree/histopathologic grade of liver injury utilizing the Combined Vascular Injury (CVI) Score in non-cancerous liver tissue post therapy compared to historical controls. CVI score will evaluate and grade sinusoidal dilation, small vessel loss/obliteration, focal hepatocyte plate disruption, parenchymal extinction lesions, nodular regenerative hyperplasia, peliosis, and veno-occlusive like changes. Rate of sinusoidal obstruction syndrome (SOS), as measured by CVI Score, ranging from 0-13. A CVI score of 3 or more indicates SOS. Compared to historical controls.

    Time frame: 8 months

Secondary outcomes

  1. To Estimate the Objective Response Rate (ORR) of SAMe when taken with oxaliplatin based chemotherapy.

    To evaluate the efficacy of SAMe during oxaliplatin based therapy in stage IV liver-only colorectal cancer, Objective Response Rate (ORR) will be measured by the proportion of patients with confirmed complete response (CR) or partial response (PR) per RECIST 1.1. ORR will be assessed from screening until EOT.

    Time frame: 8 months

  2. To evaluate changes in average estimated blood loss (EBL) in patients undergoing liver resection as compared to historical controls.

    Calculate surgical EBL in all patients undergoing resection

    Time frame: 8 months

  3. To evaluate length of hospital stay (LOS) in patients undergoing liver resection as compared to historical controls.

    Length of hospital stay (LOS) to historical controls, the following will be conducted: ii. Calculate hospital LOS in all patients undergoing resection iii. Account for 30-day readmission

    Time frame: 8 months

  4. To examine if SAMe can decrease treatment-delays in oxaliplatin-based chemotherapy.

    Incidence of oxaliplatin treatment delays will be evaluated by recording the following: If treatment delay occurred and time point/duration of treatment delay

    Time frame: 8 months

  5. To examine if SAMe can decrease dose-reductions in oxaliplatin-based chemotherapy.

    Incidence of oxaliplatin dose reduction will be evaluated by recording the following: If dose reduction occurred and time point of occurrence

    Time frame: 8 months

  6. To evaluate safety and tolerability of SAMe in combination with SOC oxaliplatin based systemic therapy.

    Safety and tolerability of the combination will be evaluated by determining the proportion of patients with treatment-related adverse events of all grades as graded per CTCAE v.5, from first dose of study drug until 30 days post last dose of study drug.

    Time frame: 8 months

07

Study locations

2 sites
  • Cedars-Sinai Medical Center at SOCC
    Los Angeles, California 90048, United States
    • Clinical Trial Recruitment Navigator · ContactGroupCancerTrialInformation@cshs.org · 310-423-5842
    • Alexandra Gangi, MD · Principal investigator
    • Jun Gong, MD · Sub investigator
    • Andrew Hendifar, MD · Sub investigator
    • Arsen Osipov, MD · Sub investigator
    • Maha Guindi, MD · Sub investigator
  • Cedars-Sinai Medical Center Beverly Hills
    Los Angeles, California 90211, United States
    • Clinical Trial Recruitment Navigator · ContactGroupCancerTrialInformation@cshs.org · 310-423-5842
    • Alexandra Gangi, MD · Principal investigator
    • Jeremy Lorber, MD · Sub investigator
    • Kevin S. Scher, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2030, 36 months later.

Of 498 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 75. This study's planned 36 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

Start moved twice since we started tracking on Sep 25, 2026: Jul 2026 → Jan 2027, last on Nov 6, 2026.

Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2028 → Jan 2030, last on Nov 6, 2026.

Completion moved twice since we started tracking on Sep 25, 2026: Aug 2028 → Jan 2030, last on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2024
First posted
Feb 14, 2024
StartEst.
Jan 2027was Jul 2026
Primary completionEst.
Jan 2030was Aug 2028
CompletionEst.
Jan 2030was Aug 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Jan 2027
moved 2 times, Sep 30, 2026 – Nov 6, 2026
Primary completion
Aug 2028→Jan 2030
moved 2 times, Sep 30, 2026 – Nov 6, 2026
Study completion
Aug 2028→Jan 2030
moved 2 times, Sep 30, 2026 – Nov 6, 2026
Contact
Study contact's phone or email changed: •••2133→•••5842. See the current contact
Sep 30, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Cedars-Sinai Medical Center at SOCC · Los Angeles, United StatesContact •••2133→•••5842
  • Cedars-Sinai Medical Center Beverly Hills · Los Angeles, United StatesContact •••2133→•••5842
Sep 30, 2026
Show all 2 updates
  1. Nov 6, 2026
    Start date Oct 2026→Jan 2027
    Primary completion Oct 2028→Jan 2030
    Study completion Oct 2028→Jan 2030
    + 1 other change: verification date
  2. Sep 30, 2026
    Start date Jul 2026→Oct 2026
    Primary completion Aug 2028→Oct 2028
    Study completion Aug 2028→Oct 2028
    Contact Study contact's phone or email changed: •••2133→•••5842. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Cedars-Sinai Medical Center at SOCC · Los Angeles, United StatesContact •••2133→•••5842
    • Cedars-Sinai Medical Center Beverly Hills · Los Angeles, United StatesContact •••2133→•••5842
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06258525
Collaborators
Jarrow Formulas Inc
Responsible party
Alexandra Gangi, MD (Sponsor-Investigator, Cedars-Sinai Medical Center) — Principal investigator
First posted
Feb 14, 2024
Start date
Jan 2027 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Trial Navigator
Contact
GroupCancerTrialInformation@cshs.org
310-423-5842
Alexandra Gangi, MD
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: S-Adenosylmethionine

Start the discussion